Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma

Milan Reinis1

  • 1Academy of Sciences of the Czech Republic, Institute of Molecular Genetics, Videnská 1083, Prague 4, CZ-14220, Czech Republic. reinis@img.cas.cz

Current Opinion in Molecular Therapeutics
|July 5, 2007
PubMed

Favrille Inc is developing FavIld, a patient-specific immunotherapy combining tumor-specific idiotype protein and keyhole limpet hemocyanin, for the potential treatment of lymphoma. A phase III clinical trial in follicular B-cell non-Hodgkin's lymphoma is underway.

Related Concept Videos